ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,847Medicare Part D Prescriptions Filled, Including Refills

Rank: 218 out of 939

$451K Total Retail Price of All Prescriptions

Rank: 304 out of 939

539 Patients Receiving at Least One Drug in Part D
74%Patients 65 Years and Older
66% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Arkansas
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

4% of this provider’s 539 patients filled at least one prescription for a schedule three drug, compared to an average of 19%.

Risky Drugs to Seniors

1% of this provider’s 8,496 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

19% of this provider’s prescriptions were for brand-name drugs, compared to an average of 21%.

Prescription Price

$42 was the average price of a prescription from this provider, compared to $49 among peers.

Prescriptions per Patient

20 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Arkansas
OMEPRAZOLE 615 507 1 5
LISINOPRIL 407 353 2 3
FUROSEMIDE 400 337 3 7
CITALOPRAM HBR 394 296 4 15
LEVOTHYROXINE SODIUM 341 307 5 4
SUCRALFATE 306 230 6 96
METOPROLOL SUCCINATE 254 202 7 21
AMLODIPINE BESYLATE 246 219 8 6
PRAVASTATIN SODIUM 244 195 9 13
FAMOTIDINE 204 143 10 62
ATENOLOL 197 154 11 19
METFORMIN HCL 190 172 12 8
GABAPENTIN 183 157 13 11
DOXAZOSIN MESYLATE 180 154 14 108
SPIRONOLACTONE 172 135 15 71
TRAMADOL HCL 168 142 16 16
GLIPIZIDE 165 147 17 52
ADVAIR DISKUS 161 126 18 60
NEXIUM 155 97 19 18
WARFARIN SODIUM 150 134 20 17
POTASSIUM CHLORIDE 147 121 21 9
CARBIDOPA-LEVODOPA 140 123 22 102
ENALAPRIL MALEATE 134 81 23 65
SIMVASTATIN 129 115 24 2
DIGOXIN 126 122 25 45
TRAZODONE HCL 114 76 26 26
LOSARTAN POTASSIUM 114 96 26 29
HYDROCHLOROTHIAZIDE 112 106 28 12
ALENDRONATE SODIUM 110 100 29 40
METOPROLOL TARTRATE 109 95 30 10
DILTIAZEM ER 109 104 30 94
CLOPIDOGREL 96 93 32 28
MELOXICAM 95 56 33 14
SPIRIVA 85 68 34 73
CIPROFLOXACIN HCL 82 64 35 54
QUETIAPINE FUMARATE 78 66 36 69
SULFAMETHOXAZOLE-TRIMETHOPRIM 77 54 37 64
PROAIR HFA 77 30 37 41
AZITHROMYCIN 75 40 39 32
PLAVIX 73 69 40 48
CARAFATE 71 66 41 209
ISOSORBIDE MONONITRATE ER 68 68 42 53
FLUCONAZOLE 65 39 43 140
TAMSULOSIN HCL 64 59 44 27
FLUOXETINE HCL 62 42 45 47
INSULIN SYRINGE 57 35 46 97
PREDNISONE 56 54 47 42
FLUTICASONE PROPIONATE 54 39 48 43
SERTRALINE HCL 52 36 49 24
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.